Ticagrelor-d7

• Description:

  Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Isotope-Labeled Compounds; P2Y Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein; Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cardiovascular Disease; Cancer

• Purity:

  97.59

• Solubility:

  10 mM in DMSO

• Smiles:

  N(C1=C2C(N(N=N2)[C@@]3(C[C@H](OCCO)[C@@H](O)[C@H]3O)[H])=NC(SC(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])=N1)[C@H]4[C@@](C4)(C5=CC(F)=C(F)C=C5)[H]

• Molecular Formula:

  C23H21D7F2N6O4S

• Molecular Weight:

  529.61

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128 (23) :2717-2728.|[3]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136 (1) :234-40.|[4]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169 (1) :82-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• Isoform:

  P2Y12 Receptor

• CAS Number:

  [1265911-55-4]